Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Wednesday. They presently have a $9.50 price objective on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on CRME. ValuEngine raised shares of Cardiome Pharma Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Zacks Investment Research cut shares of Cardiome Pharma Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Canaccord Genuity set a $8.00 price target on shares of Cardiome Pharma Corporation and gave the stock a “buy” rating in a report on Monday, August 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $5.31.

Cardiome Pharma Corporation (NASDAQ CRME) opened at $1.52 on Wednesday. Cardiome Pharma Corporation has a 1 year low of $1.29 and a 1 year high of $4.84. The company has a debt-to-equity ratio of 1.67, a quick ratio of 4.71 and a current ratio of 5.52.

Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM) last posted its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.04). Cardiome Pharma Corporation had a negative return on equity of 94.68% and a negative net margin of 112.91%. The firm had revenue of $6.02 million for the quarter, compared to the consensus estimate of $7.42 million. During the same period in the prior year, the business earned ($0.19) EPS. Cardiome Pharma Corporation’s quarterly revenue was up 14.9% compared to the same quarter last year. research analysts expect that Cardiome Pharma Corporation will post -0.82 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/cardiome-pharma-corporation-crme-rating-reiterated-by-hc-wainwright/1723342.html.

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in shares of Cardiome Pharma Corporation by 105.3% in the 1st quarter. JPMorgan Chase & Co. now owns 112,679 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 57,782 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Cardiome Pharma Corporation by 17.9% in the 1st quarter. Renaissance Technologies LLC now owns 253,413 shares of the biopharmaceutical company’s stock worth $763,000 after purchasing an additional 38,400 shares during the period. AlphaOne Investment Services LLC raised its holdings in shares of Cardiome Pharma Corporation by 14.9% in the 2nd quarter. AlphaOne Investment Services LLC now owns 632,739 shares of the biopharmaceutical company’s stock worth $2,860,000 after purchasing an additional 82,027 shares during the period. Stonepine Capital Management LLC raised its holdings in shares of Cardiome Pharma Corporation by 79.7% in the 3rd quarter. Stonepine Capital Management LLC now owns 2,866,785 shares of the biopharmaceutical company’s stock worth $6,106,000 after purchasing an additional 1,271,236 shares during the period. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Cardiome Pharma Corporation by 8.0% in the 2nd quarter. Westfield Capital Management Co. LP now owns 5,286,340 shares of the biopharmaceutical company’s stock worth $23,894,000 after purchasing an additional 391,392 shares during the period. 55.12% of the stock is currently owned by institutional investors.

About Cardiome Pharma Corporation

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.